NCT06341400View on ClinicalTrials.gov

RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions
Bladder CancerMuscle-Invasive Bladder Carcinoma
Interventions
DRUG

DisitamabVedotinForIicction Toripalimab

Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.

Trial Locations (1)

Unknown

RECRUITING

Zhujiang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
lead

Zhujiang Hospital

OTHER